6185 — Cansino Biologics Income Statement
0.000.00%
Last trade - 00:00
- HK$4.02bn
- HK$2.01bn
- CNY1.03bn
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.13 | 0 | 18.5 | 4,300 | 1,031 |
Cost of Revenue | |||||
Gross Profit | — | — | 4.74 | 3,003 | -187 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 140 | 200 | 419 | 2,388 | 2,400 |
Operating Profit | -139 | -200 | -401 | 1,912 | -1,369 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -138 | -157 | -397 | 1,937 | -1,184 |
Provision for Income Taxes | |||||
Net Income After Taxes | -138 | -157 | -397 | 1,907 | -965 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -138 | -157 | -397 | 1,914 | -909 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -138 | -157 | -397 | 1,914 | -909 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.797 | -0.698 | -1.72 | 7.73 | -3.68 |
Dividends per Share |